CoChat

Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; none of the 43 sources its claims cite is checked for support yet.

Abstract

Ethiopia has experienced a substantial resurgence in malaria in recent years, with increasing case numbers and a growing contribution of Plasmodium vivax in several regions. At the same time, new evidence supporting improved radical cure strategies, including high-dose primaquine and single-dose tafenoquine, alongside advances in molecular tools, offers opportunities to address persistent transmission and relapse. Against a backdrop of constrained funding and health system challenges, a stakeholder meeting was convened in Addis Ababa in November 2025 to review emerging evidence and discuss implications for malaria control and elimination in Ethiopia. The two-day meeting brought together 38 representatives from the National Malaria Control Programme, research institutions, regional health bureaus, and implementation partners. Key themes emerging from the meeting included: (i) systemic challenges shaping malaria control, including funding constraints, operational disruptions, and climate-related pressures; (ii) uncertainty around the contribution of relapse to overall P. vivax burden and the potential role of molecular tools to address this gap; (iii) important health system considerations for the introduction of G6PD-guided radical cure, particularly regarding service delivery levels and equity; (iv) the central role of economic evidence, with substantial uncertainty around drug pricing and implementation costs; and (v) the need for strengthened collaboration between researchers and policymakers to support evidence-informed decision-making. The meeting highlighted that, while more effective tools for P. vivax radical cure are available, their adoption in Ethiopia will depend on addressing key evidence gaps, particularly around relapse burden, feasibility, and cost-effectiveness. Given the current challenges, there is a pressing need for context specific research and continued dialogue between stakeholders, which will be critical to inform policy decisions and support progress towards malaria elimination.

Overview

CoChat Summary

TL;DR

This meeting report summarizes a November 2025 Addis Ababa stakeholder meeting on Ethiopia’s malaria resurgence and *Plasmodium vivax* radical cure, attended by 38 representatives. It concludes that high-dose primaquine, single-dose tafenoquine, and molecular tools are promising, but adoption depends on unresolved evidence gaps around relapse burden, feasibility, and cost-effectiveness.

Key findings

  • Ethiopia’s malaria burden rose from 900,000 recorded cases in 2019 to between 7.3 and 12 million cases in 2024; Ethiopia alone accounted for roughly one-third of the global increase from 2023 to 2024, and *P. vivax* contributed over 40% of cases in Amhara, >30% in Tigray, and 10–25% in Somali and Dire Dawa.
  • Ethiopia currently uses low-dose primaquine (3.5 mg/kg total dose over 14 days) without G6PD testing, but evidence supports high-dose primaquine (7 mg/kg total dose) and single-dose tafenoquine (300 mg); the national programme does not yet prioritize these due to cost concerns and uncertainty about relapse versus new infections.
  • Health-system delivery is uncertain: national policy expects about 70% of malaria cases to be diagnosed and treated at health posts and 30% at health centres, but G6PD-guided radical cure may be challenging at health posts, and some areas report up to 70% of patients seeking care at health centres.
  • Economic evidence was central: preliminary modelling suggested tafenoquine could be cost-saving versus high-dose primaquine under some assumed procurement prices, but this reversed under alternative prices; stakeholders preferred a societal perspective and malaria cases averted as the primary outcome, while no consensus emerged on modelling intermediate G6PD activity or day 3 review visits.

Methods

  • A two-day stakeholder meeting, “Building the toolkit to address malaria resurgence and radical cure in Ethiopia,” was held on 28–29 November 2025 in Addis Ababa and convened 38 representatives from the National Malaria Control Programme, Ethiopian research institutions, five regional malaria focal persons (Amhara, Tigray, Somali, Gambella, and Dire Dawa), and implementation partners.
  • Day 1 covered malaria priorities and resurgence, radical cure evidence, and operational/economic considerations, including an interactive Mentimeter question-and-answer session; Day 2 focused on practical use cases for molecular tools, with short presentations followed by moderated roundtable discussions.
  • Notes were taken and collated to present key discussion points; the report synthesizes themes qualitatively and does not report primary data collection or statistical analysis.

Limitations

  • The authors state that molecular tools to distinguish relapse from reinfection are not yet fully validated and remain confined to academic research; there are no validated molecular markers for *P. vivax* drug resistance, including chloroquine, and sampling, cost, and classification uncertainty remain.
  • The authors note substantial uncertainty around primaquine and tafenoquine costs, no consensus on modelling intermediate G6PD activity or follow-up visits, and no explicit cost-effectiveness threshold for Ethiopia.
  • Evident from the text: as a meeting report, the findings reflect stakeholder discussion and personal communication rather than a systematic review or primary study, and no formal consensus or quantitative synthesis is reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-026-06050-4

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Selected results from the interactive health economics discussions
Fig. 1 Selected results from the interactive health economics discussionsCC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 22 Not checked · 9 Own results and interpretations

10 more claims

Create a free account to see all 31 claims and to verify the 40 references still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 35 references

Cited by

See all 1

Metadata

Authors
Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., Puoch, K., Abdelmenan, S., Mesfin, M., Hailemichael, Y., Gadisa, E., Hailu, D., Beyene, E., Lankir, D., Teklu, G., Mamo, H., Amare, E., Etana, K., Temesgen, Y., Nigusse, B., Adissu, W., Hailu, A., Yewhalaw, D., Kebede, A., Abanegash, J., Teka, H., Legese, S., Getachew, A., Abdi, B., Minale, M., Abera, A., Tasew, G., Tafess, K., Sisay, A., Seyoum, N., Dilu, D., Aliyi, A., Devine, A., Assefa, A., Auburn, S., & Thriemer, K.
Affiliations
  • Charles Darwin University (AU)
  • Ethiopian Public Health Institute (ET)
  • Arba Minch University (ET)
  • Program for Appropriate Technology in Health (US)
  • Addis Continental Institute of Public Health (ET)
  • Armauer Hansen Research Institute (ET)
  • Amhara Regional Health Bureau (ET)
  • Aksum University (ET)
  • Addis Ababa University (ET)
  • Federal Ministry of Health (ET)
  • Jimma University (ET)
  • Adama Science and Technology University (ET)
  • The University of Melbourne (AU)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Thriemer, Kamala
Venue
Malaria Journal
Published
2026-07-31
Volume
25
Issue
1
Pages
278
ISSN
1475-2875 (ISSN-L)
OpenAlex
W7171842801
Cited by
1
References
33
Citations by year
2026: 1
FWCI
3.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Bill and Melinda Gates Foundation (INV-043618, INV-024389)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Social Sciences › Arts and Humanities › History › History of Medicine and Tropical Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
Keywords
malaria resurgence, Plasmodium vivax, radical cure, primaquine, tafenoquine, relapse, glucose-6-phosphate dehydrogenase, malaria elimination, malaria control, health system challenges, drug pricing, cost-effectiveness, evidence-informed policy, Ethiopia
MeSH terms
Antimalarials, Ethiopia, Humans, Plasmodium vivax, Malaria, Vivax, Communicable Diseases, Emerging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report. https://app.cochat.ai/papers/10.1186/s12936-026-06050-4
The paper
Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., Puoch, K., Abdelmenan, S., Mesfin, M., Hailemichael, Y., Gadisa, E., Hailu, D., Beyene, E., Lankir, D., Teklu, G., . . . Thriemer, K. (2026). Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report. Malaria Journal. https://doi.org/10.1186/s12936-026-06050-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.